In the above-cited study by Tam et al. [159], the combination of the anti-TNFR2 antibody Y9 with its assumed FcγR-dependent agonism and a PDL1 blocking antibody resulted in superior anti-tumor activity. This evidence concerns the gene TNFRSF1B and neoplasm.